Histone deacetylases and cancer: causes and therapies

[1]  R. Evans,et al.  Isolation and Characterization of Mammalian HDAC10, a Novel Histone Deacetylase* , 2002, The Journal of Biological Chemistry.

[2]  S. Leit,et al.  Design and synthesis of a novel class of histone deacetylase inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[3]  V. Richon,et al.  Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.

[4]  M. Guenther,et al.  Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen* , 2001, The Journal of Biological Chemistry.

[5]  Richard A. Rifkind,et al.  Cloning and characterization of a histone deacetylase, HDAC9 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  L. Grochow,et al.  A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  S. Kyo,et al.  Telomerase activation by histone deacetylase inhibitor in normal cells. , 2001, Nucleic acids research.

[8]  P. Parsons,et al.  Histone Hyperacetylation Induced by Histone Deacetylase Inhibitors Is Not Sufficient to Cause Growth Inhibition in Human Dermal Fibroblasts* , 2001, The Journal of Biological Chemistry.

[9]  P. Marks,et al.  The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. , 2001, Cancer research.

[10]  C. Glass,et al.  Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome. , 2001, Human molecular genetics.

[11]  P. Gregory,et al.  Histone acetylation and chromatin remodeling. , 2001, Experimental cell research.

[12]  T. Naoe,et al.  In vivo Effects of a Histone Deacetylase Inhibitor, FK228, on Human Acute Promyelocytic Leukemia in NOD/Shi‐scid/scid Mice , 2001, Japanese journal of cancer research : Gann.

[13]  A. Harel-Bellan,et al.  Histone acetylation and disease , 2001, Cellular and Molecular Life Sciences CMLS.

[14]  Eun-Joung Moon,et al.  Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes , 2001, Nature Medicine.

[15]  C. Cordon-Cardo,et al.  Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  A. Verdel,et al.  Functional significance of histone deacetylase diversity. , 2001, Current opinion in genetics & development.

[17]  K. Struhl,et al.  Histone Acetylation at Promoters Is Differentially Affected by Specific Activators and Repressors , 2001, Molecular and Cellular Biology.

[18]  S. Croft,et al.  The synthesis of cyclic tetrapeptoid analogues of the antiprotozoal natural product apicidin. , 2001, Bioorganic & medicinal chemistry letters.

[19]  P. Liberator,et al.  Histone deacetylase: a target for antiproliferative and antiprotozoal agents. , 2001, Current medicinal chemistry.

[20]  T. Ekström,et al.  The human histone deacetylase family. , 2001, Experimental cell research.

[21]  M. Yoshida,et al.  Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Marks,et al.  Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Schmatz,et al.  Synthesis of apicidin-derived quinolone derivatives: parasite-selective histone deacetylase inhibitors and antiproliferative agents. , 2000, Journal of medicinal chemistry.

[24]  S. Schreiber,et al.  Genomewide studies of histone deacetylase function in yeast. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Carducci,et al.  Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors , 2000, Expert opinion on investigational drugs.

[26]  A. Wolffe,et al.  Chromatin organisation and human disease , 2000 .

[27]  R A Rifkind,et al.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.

[28]  Y. Yan-Neale,et al.  HDAC1, a histone deacetylase, forms a complex with Hus1 and Rad9, two G2/M checkpoint Rad proteins. , 2000, The Journal of biological chemistry.

[29]  I. Adcock,et al.  Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-1β-Induced Histone H4 Acetylation on Lysines 8 and 12 , 2000, Molecular and Cellular Biology.

[30]  P. Marks,et al.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[32]  E. Olson,et al.  Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. , 2000, Molecular cell.

[33]  R. Frye,et al.  Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. , 2000, Biochemical and biophysical research communications.

[34]  Peter L. Jones,et al.  DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters , 2000, Nature Genetics.

[35]  W. D. Cress,et al.  Histone deacetylases, transcriptional control, and cancer , 2000, Journal of cellular physiology.

[36]  S. Kern,et al.  A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. , 2000, Cancer research.

[37]  R. Sternglanz,et al.  The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Tony Kouzarides,et al.  Acetylation: a regulatory modification to rival phosphorylation? , 2000, The EMBO journal.

[39]  R. Ricciardi,et al.  Association of histone deacetylase with COUP-TF in tumorigenic Ad12-transformed cells and its potential role in shut-off of MHC class I transcription. , 2000, Virology.

[40]  Carlos Caldas,et al.  Mutations truncating the EP300 acetylase in human cancers , 2000, Nature Genetics.

[41]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[42]  D. Cohen,et al.  Histone Deacetylase Inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and Antiproliferative Effects* , 1999, The Journal of Biological Chemistry.

[43]  S. Grant,et al.  Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53 , 1999, Oncogene.

[44]  P. Marks,et al.  Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). , 1999, Anticancer research.

[45]  M. Grunstein,et al.  Yeast HOS3 forms a novel trichostatin A-insensitive homodimer with intrinsic histone deacetylase activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[47]  R. Kornberg,et al.  Twenty-Five Years of the Nucleosome, Fundamental Particle of the Eukaryote Chromosome , 1999, Cell.

[48]  T. Suzuki,et al.  Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. , 1999, Journal of medicinal chemistry.

[49]  Y. Saunthararajah,et al.  Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. , 1999, Cancer research.

[50]  Hengyi Xiao,et al.  Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells , 1999, Journal of cellular biochemistry.

[51]  D. Fairlie,et al.  Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate , 1999, British Journal of Cancer.

[52]  B. Asch,et al.  Epigenetic regulation of gelsolin expression in human breast cancer cells. , 1999, Experimental cell research.

[53]  S. Horinouchi,et al.  Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase , 1999, Oncogene.

[54]  T. Tsuruo,et al.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[55]  P. Pandolfi,et al.  Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. , 1998, Journal of the National Cancer Institute.

[56]  R. Evans,et al.  The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. , 1998, Nucleic acids research.

[57]  K. Blanchard,et al.  Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. , 1998, Blood.

[58]  T. Hoshino,et al.  ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[59]  M. Yoshida,et al.  FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. , 1998, Experimental cell research.

[60]  M. Breuning,et al.  Conjunction dysfunction: CBP/p300 in human disease. , 1998, Trends in genetics : TIG.

[61]  J. Davie,et al.  Covalent modifications of histones: expression from chromatin templates. , 1998, Current opinion in genetics & development.

[62]  S. Schreiber,et al.  Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[63]  P. Marks,et al.  A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[64]  F. Behm,et al.  All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. , 1997, Blood.

[65]  M. Jung,et al.  Analogues of trichosтatin a and trapoxin B as histone deacetylase inhibitors , 1997 .

[66]  D. Fairlie,et al.  Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells. , 1997, Biochemical pharmacology.

[67]  C. Disteche,et al.  The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB–binding protein , 1996, Nature Genetics.

[68]  R A Rifkind,et al.  Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[69]  S. Horinouchi,et al.  Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

[70]  K. Kinzler,et al.  p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. , 1995, Genes & development.

[71]  J. Lupton,et al.  Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. , 1994, Cancer letters.

[72]  M. Yoshida,et al.  Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. , 1993, The Journal of biological chemistry.

[73]  H. Nagahara,et al.  Loss of heterozygosity on chromosome 16 in hepatocellular carcinoma , 1992, Journal of gastroenterology and hepatology.

[74]  P. Marks,et al.  A new group of potent inducers of differentiation in murine erythroleukemia cells. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[75]  W. Scher,et al.  Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[76]  T. Tsuruo,et al.  Activity Synthetic Histone Deacetylase Inhibitor with Antitumor Cyclic Hydroxamic-acid-containing Peptide 31 , a Potent Updated Version , 2001 .

[77]  Lili Huang,et al.  Molecular Medicine © 2000 The Picower Institute Press Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment , 2000 .

[78]  S. Hiebert,et al.  Role of histone deacetylases in acute leukemia , 1998, Journal of cellular biochemistry.

[79]  C. Van Lint,et al.  The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. , 1996, Gene expression.

[80]  Allfrey Vg.  Structural modifications of histones and their possible role in the regulation of ribonucleic acid synthesis. , 1966 .

[81]  D. Hoelzer,et al.  Molecular Medicine © 2000 The Picower Institute Press Review Article Histone Acetylation Modifiers in the Pathogenesis of Malignant Disease , 2022 .